NCT07123090 - A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

October 1, 2026

Study Completion Date

February 1, 2028

Conditions

Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaKidney CancerTranslocation Renal Cell Carcinoma

Interventions

DRUG

Sasanlimab

Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol

DRUG

Palbociclib

Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol

DRUG

Axitinib

Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care

Trial Locations (2)

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston